Researchers have used a chemical compound to light up treatment-resistant cancers on imaging scans, in a breakthrough that ...
19h
GlobalData on MSNGSK’s lung cancer therapy gains EMA PRIME designationGlaxoSmithKline (GSK)’s B7-H3-targeted antibody-drug conjugate (ADC), GSK’227 has gained priority medicines (PRIME) ...
New findings from the NC Department of Health and Human Services reveal high radon levels detected in 77 out of 100 North ...
The FDA delays Johnson & Johnson's SC amivantamab approval for NSCLC over facility inspection issues, unrelated to product ...
The FDA issues a complete response letter to JNJ's BLA seeking approval for the subcutaneous formulation of Rybrevant in EGFR ...
12h
News Medical on MSNChemical compound lights up treatment-resistant cancers on imaging scansResearchers have used a chemical compound to light up treatment-resistant cancers on imaging scans, in a breakthrough that could help medical professionals better target and treat cancer.
Researchers have used a chemical compound to light up treatment-resistant cancers on imaging scans, in a breakthrough that could help medical ...
9h
Soycarmin(English) on MSNCancer Vaccine Launched, Wipes Out MetastasisA promising breakthrough in the fight against cancer emerges from Russia. The cancer vaccine developed by the Gamaleya Center ...
GSK’s B7-H3-targeted ADC, GSK’227, receives EMA PRIME designation in relapsed extensive-stage small-cell lung cancer: London, UK Tuesday, December 17, 2024, 12:00 Hrs [IST] GS ...
Johnson & Johnson (JNJ) injectable cancer drug Rybrevant developed with Halozyme (HALO) is declined by the FDA due to ...
After years of fighting for full reparations, the community of Piquiá de Baixo in the Brazilian state of Maranhão secured ...
Merck's strong financial performance in oncology and vaccines drove a 9% sales increase earlier in Q1 of 2024. See why I rate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results